Isoliquiritigenin in breast cancer therapy: from mechanistic insights to advanced nano-enabled delivery strategies.
Isoliquiritigenin (ISL), a chalcone from Glycyrrhiza species, exhibits multi-target anti-breast cancer activity but faces pharmacokinetic limitations. This review synthesizes evidence for ISL's molecular targets and mechanisms and evaluates nano-delivery strategies. In preclinical models, ISL inhibits proliferation via...